Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania.
Clin Gastroenterol Hepatol. 2023 Jan;21(1):232-233. doi: 10.1016/j.cgh.2022.08.017. Epub 2022 Aug 25.
SARS-CoV-2 was first identified in Wuhan in December 2019 and since then it has progressed into a pandemic that evolves continuously. As of May 5, 2022, there have been more than 81 million cases and 994,187 deaths in the United States. Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract consisting of ulcerative colitis and Crohn's disease treated with immunosuppressive/immunomodulatory agents. Over the course of the pandemic different aspects of the interaction between SARS-COV-2 and IBD medications have been studied. At the onset of the pandemic there was decreased use of infusible biologics. Despite the passage of time an area that has not been explored is the impact of biologics on the clinical course of SARS-COV-2 when given soon after the detection of infection. Our aim was to determine the impact of biologics on the clinical course of SARS-COV-2 among patients with IBD, when given 1-2 weeks postinfection among stable patients. This is of critical importance because patients may delay getting their scheduled treatment, which in turn could adversely affect their clinical condition.
SARS-CoV-2 于 2019 年 12 月在中国武汉首次被发现，此后已发展成为一种不断演变的大流行疾病。截至 2022 年 5 月 5 日，美国已有超过 8100 万例病例和 994187 例死亡。炎症性肠病（IBD）是一种胃肠道慢性炎症性疾病，包括溃疡性结肠炎和克罗恩病，采用免疫抑制/免疫调节剂治疗。在大流行期间，人们研究了 SARS-CoV-2 和 IBD 药物之间相互作用的不同方面。在大流行开始时，输注型生物制剂的使用减少了。尽管时间已经过去，但尚未探索的一个领域是生物制剂在感染检测后不久给予时对 SARS-CoV-2 临床病程的影响。我们的目的是确定在感染后 1-2 周内稳定患者中给予生物制剂对 IBD 患者 SARS-CoV-2 临床病程的影响。这一点至关重要，因为患者可能会延迟接受他们的预定治疗，这反过来又可能对他们的临床状况产生不利影响。
